Shao-Lee Lin Sells 40,000 Shares of Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00. Following the completion of the sale, the chief executive officer owned 724,253 shares of the company’s stock, valued at approximately $19,627,256.30. The trade was a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Thursday, August 13th, Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock. The shares were sold at an average price of $28.62, for a total value of $522,543.96.

Cue Biopharma Price Performance

Shares of NASDAQ:CUE opened at $34.20 on Friday. The business’s 50 day simple moving average is $29.50 and its 200 day simple moving average is $147.28. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50. The company has a market capitalization of $143.64 million, a P/E ratio of -1.27 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The company had revenue of $7.88 million during the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on CUE shares. Weiss Ratings raised Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Key Headlines Impacting Cue Biopharma

Here are the key news stories impacting Cue Biopharma this week:

• Positive Sentiment: Second-quarter 2026 revenue was $7.88 million, well above analysts’ $3.00 million estimate. The company also reported recent business highlights, providing potentially supportive news for its clinical-stage immunotherapy pipeline. Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Neutral Sentiment: Institutional ownership stands at approximately 35.04%, with several funds increasing their positions in recent quarters. This suggests some investor interest, although the reported holdings are relatively small compared with the company’s market capitalization.
• Neutral Sentiment: CEO Shao-Lee Lin sold a combined 58,258 shares for about $1.61 million across August 12 and 13. The filings state that the sales were intended to cover tax-withholding obligations related to vested equity awards, reducing the significance of the transactions as a discretionary bearish signal. Lin still owned 705,995 shares after the latest sale. Cue Biopharma CEO Sells Stock
• Negative Sentiment: Cue Biopharma reported a quarterly loss of $24.14 per share, far worse than the consensus estimate of a $1.69 loss. The company also posted a negative net margin of 59.65% and negative return on equity of 98.30%, highlighting ongoing profitability and potential financing risks.
• Negative Sentiment: Wall Street Zen downgraded CUE from “Buy” to “Hold.” MarketBeat said the broader analyst consensus remains “Sell,” with one tracked analyst carrying a Sell rating. Wall Street Zen Downgrades Cue Biopharma

Institutional Investors Weigh In On Cue Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Cue Biopharma in the 2nd quarter valued at $83,000. Persistent Asset Partners Ltd acquired a new position in shares of Cue Biopharma during the 2nd quarter worth $389,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Cue Biopharma during the 2nd quarter worth $722,000. ADAR1 Capital Management LLC bought a new stake in shares of Cue Biopharma during the 2nd quarter worth $1,742,000. Finally, BlackRock Inc. bought a new stake in shares of Cue Biopharma during the 2nd quarter worth $1,824,000. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Company Profile

Cue Biopharma is a clinical?stage biotechnology company focused on the development of next?generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen?specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early?stage clinical studies.